semaglutide thyroid side effects What are the long-term of after 3+ years Semaglutide-induced Subclinical Hypothyroidism: A Case

Background on Semaglutide Semaglutide has emerged as a cornerstone in the management of type 2 diabetes and obesity, heralding a new era in the therapeutic landscape of these chronic conditions

Vandetanib, trade name Caprelsa, was the first drug (April 2011) to be approved by US Food and Drug Administration (FDA) for treatment of late-stage (metastatic) medullary thyroid cancer in adult patients who are ineligible for surgery

See Physician Log in prior to appointment using emailed link and prepared with questions for the physician

PMCID: PMC6895888 Remvig L, Duhn PH, Ullman S, Kobayasi T, Hansen B, Juul-Kristensen B, Jurvelin JS, Arokoski J